Trial Profile

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DAN-222 (Primary) ; Niraparib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Dantari

Most Recent Events

09 Dec 2023 Results presented at the 46th Annual San Antonio Breast Cancer Symposium
07 Dec 2023 Status changed from active, no longer recruiting to completed.
07 Dec 2023 According to Dantari media release, data from this study will be presented at 2023 San Antonio Breast Cancer Symposium (SABCS).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com